In this study, combination therapy with LIMK1 and CDK5 inhibitors exhibited a significant therapeutic effect on ESCC metastasis in a preclinical setting, as well as in EAC, gastric cancer, and lung cancer metastasis. Here, CDK5 is linked to lung carcinoma.